Exchange: NASDAQ·Updated 07:58 PM EST

TNXP News

News
all
press releases
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
More News
Tonix announced a second commercial payer agreement for Tonmya, its fibromyalgia treatment.
Stocktwits
Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial payer agreement for fibromyalgia drug TONMYA.read more...
Benzinga
The company announced a new agreement with a major group purchasing organization which opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S.
Stocktwits
Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.read more...
Benzinga
TD Cowen raised Tonix Pharmaceuticals to a "strong-buy" rating in a report on Tuesday...
MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-tonix-pharmaceuticals-holding-corp-stock...
MarketBeat
The company said on Friday that it now expects a net loss for the first quarter of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.
Stocktwits
Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat
Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat

Advertisement|Remove ads.